---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-022931"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:52:17.083411+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics receives FDA Fast Track for CTIM-76 in platinum-resistant ovarian cancer

## Summary
- FDA granted Fast Track Designation for CTIM-76 (CLDN6 x CD3 bispecific antibody) in PROC after all standard therapies.
- Phase 1a trial evaluating CTIM-76 in CLDN6-positive ovarian, endometrial, and testicular cancers is ongoing.
- Interim data from the Phase 1a trial expected in June 2026.
- Fast Track aims to expedite development and review for serious conditions with unmet need.

## SEC filing metadata
- accession: 0001628280-26-022931
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000162828026022931/0001628280-26-022931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000162828026022931/cntx-20260402.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-022931
- JSON: https://secwatch.observer/filing/0001628280-26-022931.json
- Plain text: https://secwatch.observer/filing/0001628280-26-022931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.